KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Equity Average (2019 - 2025)

Takeda Pharmaceutical has reported Equity Average over the past 7 years, most recently at $47.3 billion for Q1 2025.

  • For Q1 2025, Equity Average fell 2.65% year-over-year to $47.3 billion; the TTM value through Mar 2025 reached $47.3 billion, down 2.65%, while the annual FY2026 figure was $48.6 billion, 2.71% up from the prior year.
  • Equity Average was $47.3 billion for Q1 2025 at Takeda Pharmaceutical, down from $48.6 billion in the prior quarter.
  • Across five years, Equity Average topped out at $48.9 billion in Q1 2022 and bottomed at $46.2 billion in Q1 2021.
  • The 5-year median for Equity Average is $48.5 billion (2023), against an average of $47.9 billion.
  • Year-over-year, Equity Average increased 5.96% in 2022 and then decreased 2.65% in 2025.
  • Over 5 years, Equity Average stood at $46.2 billion in 2021, then increased by 5.96% to $48.9 billion in 2022, then fell by 0.89% to $48.5 billion in 2023, then rose by 0.16% to $48.6 billion in 2024, then decreased by 2.65% to $47.3 billion in 2025.
  • The last three reported values for Equity Average were $47.3 billion (Q1 2025), $48.6 billion (Q1 2024), and $48.5 billion (Q1 2023) per Business Quant data.